Cambridge, UK and Indianapolis, US – 9 July 2019: Acacia Pharma Group plc ( the "Company), (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that on 9 July 2019, the Directors and PDMR detailed in the notifications below purchased Ordinary Shares pursuant to the deferral of a proportion of their annual cash bonus earned in 2018.  Both the Directors and the PDMR have undertaken to retain such shares until at least 31 December 2020.

The number of Ordinary Shares purchased by each Director and the PDMR is set out below:
               

DirectorNumber of Ordinary Shares purchased
Julian Gilbert6,043
Christine Soden5,600
PDMR 
Gabriel Fox5,098

Following these trades, the beneficial interest of each Director and the PDMR in Ordinary Shares in the Company is as follows:

DirectorNumber of Ordinary Shares heldPercentage of issued share capital
Julian Gilbert846,9981.588%
Christine Soden56,1750.11%
PDMR  
Gabriel Fox*328,5760.62%

*          Dr Fox holds 52,631 of these shares through Comedica Consulting Limited, a company owned by Dr Fox’s spouse.

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provide further details:

1Details of the person discharging managerial responsibilities/person closely associated
a)NameJulian Gilbert
2Reason for the notification
a)Position/status Chief Executive Officer
b)Initial notification/ Amendment Initial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameAcacia Pharma Group plc 
b)LEI213800SLDKXWKT6E3381
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument

 

Identification code 
Ordinary Shares of £0.02 each

 

 

 

GB00BYWF9Y76
b)Nature of the transactionShare purchase 
c)Price(s) and volume(s)6,043 Ordinary Shares at a price of £2.04 per share
d)Aggregated information
- Aggregated volume
- Price

 
N/A
e)Date of the transaction9 July 2019

 
f)Place of the transactionEuronext Brussels (XBRU)


1Details of the person discharging managerial responsibilities/person closely associated
a)NameChristine Soden
2Reason for the notification
a)Position/status Chief Financial Officer
b)Initial notification/ Amendment Initial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameAcacia Pharma Group plc 
b)LEI213800SLDKXWKT6E3381
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument

 

Identification code 
Ordinary Shares of £0.02 each

 

 

 

GB00BYWF9Y76
b)Nature of the transactionShare purchase 
c)Price(s) and volume(s)5,600 Ordinary Shares at a price of £1.70 per share
d)Aggregated information
- Aggregated volume
- Price

 
N/A
e)Date of the transaction9 July 2019

 
f)Place of the transactionEuronext Brussels (XBRU)


1Details of the person discharging managerial responsibilities/person closely associated
a)NameDr Gabriel Fox
2Reason for the notification
a)Position/status Chief Medical Officer/PDMR
b)Initial notification/ Amendment Initial notification
3Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameAcacia Pharma Group plc 
b)LEI213800SLDKXWKT6E3381
4Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument

 

Identification code 
Ordinary Shares of £0.02 each

 

 

 

GB00BYWF9Y76
b)Nature of the transactionShare purchase 
c)Price(s) and volume(s)5,098 Ordinary Shares at a price of £1.77 per share
d)Aggregated information
- Aggregated volume
- Price

 
N/A
e)Date of the transaction9 July 2019

 
f)Place of the transactionEuronext Brussels (XBRU)

Contacts 

Acacia Pharma Group plc
Julian Gilbert, CEO
Christine Soden, CFO
+44 1223 919760
Citigate Dewe Rogerson 
Mark Swallow, Shabnam Bashir, David Dible
+44 20 7638 9571